Taiho, Otsuka, Chugai, Biocon and Mark Alles—FiercePharmaAsia by Angus Liu Friday, January 10, 2020 Taiho, Otsuka and Chugai wins KRAS-focused licensing deals. Biocon Biologics nabs PE funding before planned IPO. Mark Alles joins Antengene's board.
Verastem wins FDA nod for AbbVie-ditched cancer drug Copiktra by Angus Liu Tuesday, September 25, 2018 The first dual PI3K-delta/gamma inhibitor will go up against Gilead's Zydelig, the first PI3K inhibitor, and Bayer’s Aliqopa.
